Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations

Inhibitors of monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT) are major strategies to reduce levodopa degradation and thus to increase and prolong its effect in striatal dopaminergic neurotransmission in Parkinson’s disease patients. While selegiline/rasagiline and tolcapone/enta...

Descripción completa

Detalles Bibliográficos
Autores principales: Regensburger, Martin, Ip, Chi Wang, Kohl, Zacharias, Schrader, Christoph, Urban, Peter P., Kassubek, Jan, Jost, Wolfgang H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2023
Materias:
Neurology and Preclinical Neurological Studies - Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199833/
https://www.ncbi.nlm.nih.gov/pubmed/36964457
http://dx.doi.org/10.1007/s00702-023-02623-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199833/
https://www.ncbi.nlm.nih.gov/pubmed/36964457
http://dx.doi.org/10.1007/s00702-023-02623-8

Ejemplares similares